These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 2889215

  • 1. Current concept for improving treatment of prostate cancer based on combination of LH-RH agonists with other agents.
    Schally AV, Redding TW, Paz-Bouza JI, Comaru-Schally AM, Mathe G.
    Prog Clin Biol Res; 1987; 243A():173-97. PubMed ID: 2889215
    [No Abstract] [Full Text] [Related]

  • 2. Current treatment of advanced prostate cancer.
    Ismail M, Gomella LG.
    Tech Urol; 1997; 3(1):16-24. PubMed ID: 9170220
    [Abstract] [Full Text] [Related]

  • 3. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N, Arima K, Sugimura Y.
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [Abstract] [Full Text] [Related]

  • 4. [Maximal androgen blockade in the treatment of patients with disseminated cancer of the prostate].
    Matveev BP, Bukharkin BV.
    Vopr Onkol; 1998 Sep; 44(5):537-40. PubMed ID: 9884710
    [Abstract] [Full Text] [Related]

  • 5. Endocrine treatment of prostate cancer.
    Tammela T.
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [Abstract] [Full Text] [Related]

  • 6. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.
    Moul JW.
    Cancer; 2009 Aug 01; 115(15):3376-8. PubMed ID: 19484788
    [No Abstract] [Full Text] [Related]

  • 7. Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
    Prescrire Int; 2007 Dec 01; 16(92):243. PubMed ID: 18092407
    [Abstract] [Full Text] [Related]

  • 8. Combination therapy with flutamide and [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide in stage C and D prostate cancer: today's therapy of choice--rationale and 5-year clinical experience.
    Labrie F, Dupont A, Cusan L, Bélanger A, Giguère M, Labrie C, Lacourcière Y, Monfette G, Emond J.
    Prog Clin Biol Res; 1988 Dec 01; 262():11-63. PubMed ID: 3287388
    [No Abstract] [Full Text] [Related]

  • 9. Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancer.
    Labrie F, Dupont A, Cusan L, Gomez JL, Diamond P.
    Clin Invest Med; 1993 Dec 01; 16(6):493-8. PubMed ID: 8013154
    [Abstract] [Full Text] [Related]

  • 10. Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis.
    Koutsilieris M, Dimopoulos T, Milathianakis C, Bogdanos J, Karamanolakis D, Pissimissis N, Halapas A, Lembessis P, Papaioannou A, Sourla A.
    BJU Int; 2007 Jul 01; 100 Suppl 2():60-2. PubMed ID: 17594363
    [No Abstract] [Full Text] [Related]

  • 11. A review of the use of histrelin acetate in the treatment of prostate cancer.
    Crawford ED.
    BJU Int; 2009 Mar 01; 103 Suppl 2():14-22. PubMed ID: 19228148
    [No Abstract] [Full Text] [Related]

  • 12. Hormonal treatment for progression.
    Miller K.
    Eur J Cancer; 2009 Sep 01; 45 Suppl 1():158-60. PubMed ID: 19775614
    [No Abstract] [Full Text] [Related]

  • 13. [Treatment of carcinoma of the prostate with analogs of LHRH].
    Rubio Herrera MA, Calle Fernández JR.
    Rev Clin Esp; 1986 Nov 01; 179(8):407-11. PubMed ID: 2951782
    [No Abstract] [Full Text] [Related]

  • 14. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
    Chertin B, Spitz IM, Lindenberg T, Algur N, Zer T, Kuzma P, Young AJ, Catane R, Farkas A.
    J Urol; 2000 Mar 01; 163(3):838-44. PubMed ID: 10687989
    [Abstract] [Full Text] [Related]

  • 15. Histologic changes in the rat prostate cancer model after treatment with somatostatin analogs and D-Trp-6-LH-RH.
    Zalatnai A, Paz-Bouza JI, Redding TW, Schally AV.
    Prostate; 1988 Mar 01; 12(1):85-98. PubMed ID: 2894651
    [Abstract] [Full Text] [Related]

  • 16. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A.
    Clin Cancer Res; 2003 Oct 01; 9(12):4505-13. PubMed ID: 14555524
    [Abstract] [Full Text] [Related]

  • 17. [History of clinical studies on hypothalamic hormone analogs in Mexico].
    Schally AV, González Bárcena D.
    Gac Med Mex; 2006 Oct 01; 142(4):315-25. PubMed ID: 17022307
    [Abstract] [Full Text] [Related]

  • 18. Combination hormonal therapy: a reassessment within advanced prostate cancer.
    Moul JW, Chodak G.
    Prostate Cancer Prostatic Dis; 2004 Sep 01; 7 Suppl 1():S2-7. PubMed ID: 15365575
    [Abstract] [Full Text] [Related]

  • 19. Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer.
    Schally AV, Comaru-Schally AM, Gonzalez-Barcena D.
    Biomed Pharmacother; 1992 Sep 01; 46(10):465-71. PubMed ID: 1363977
    [Abstract] [Full Text] [Related]

  • 20. [The effects of LH-RH agonist alone or with flutamide in the treatment of stage D2 prostate cancer].
    Ito T, Aizawa T, Yamamoto S, Ohkubo Y, Tsujino S, Miki M.
    Hinyokika Kiyo; 1998 Jul 01; 44(7):477-80. PubMed ID: 9752601
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.